RETRA

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H562309

CAS#: 1035875-01-4

Description: RETRA is an anticancer agent. It acts by exerting anticancer activity in Ewing's sarcoma cells independent of their TP53 status.


Chemical Structure

img
RETRA
CAS# 1035875-01-4

Theoretical Analysis

Hodoodo Cat#: H562309
Name: RETRA
CAS#: 1035875-01-4
Chemical Formula: C11H12BrNO3S2
Exact Mass: 0.00
Molecular Weight: 350.240
Elemental Analysis: C, 37.72; H, 3.45; Br, 22.81; N, 4.00; O, 13.70; S, 18.31

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: RETRA;

IUPAC/Chemical Name: 2-[(4,5-Dihydro-2-thiazolyl)thio]-1-(3,4-dihydroxyphenyl)-ethanone hydrobromide

InChi Key: GUNFIDRZOBRQCN-UHFFFAOYSA-N

InChi Code: InChI=1S/C11H11NO3S2.BrH/c13-8-2-1-7(5-9(8)14)10(15)6-17-11-12-3-4-16-11;/h1-2,5,13-14H,3-4,6H2;1H

SMILES Code: OC1=CC=C(C(CSC2=NCCS2)=O)C=C1O.[H]Br

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 350.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Retra K, deWalick S, Schmitz M, Yazdanbakhsh M, Tielens AG, Brouwers JF, van Hellemond JJ. The tegumental surface membranes of Schistosoma mansoni are enriched in parasite-specific phospholipid species. Int J Parasitol. 2015 Aug;45(9-10):629-36. doi: 10.1016/j.ijpara.2015.03.011. Epub 2015 May 11. PubMed PMID: 25975668.

2: Sonnemann J, Grauel D, Blümel L, Hentschel J, Marx C, Blumrich A, Focke K, Becker S, Wittig S, Schinkel S, Krämer OH, Beck JF. RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their TP53 status. Eur J Cancer. 2015 May;51(7):841-51. doi: 10.1016/j.ejca.2015.02.016. Epub 2015 Mar 19. PubMed PMID: 25801700.

3: Santag S, Jäger W, Karsten CB, Kati S, Pietrek M, Steinemann D, Sarek G, Ojala PM, Schulz TF. Recruitment of the tumour suppressor protein p73 by Kaposi's Sarcoma Herpesvirus latent nuclear antigen contributes to the survival of primary effusion lymphoma cells. Oncogene. 2013 Aug 8;32(32):3676-85. doi: 10.1038/onc.2012.385. Epub 2012 Sep 10. PubMed PMID: 22964633.

4: Edink E, Rucktooa P, Retra K, Akdemir A, Nahar T, Zuiderveld O, van Elk R, Janssen E, van Nierop P, van Muijlwijk-Koezen J, Smit AB, Sixma TK, Leurs R, de Esch IJ. Fragment growing induces conformational changes in acetylcholine-binding protein: a structural and thermodynamic analysis. J Am Chem Soc. 2011 Apr 13;133(14):5363-71. doi: 10.1021/ja110571r. Epub 2011 Feb 15. PubMed PMID: 21322593.

5: Eisterer W, Hussl C, Erb H, Haslbauer F, Sormann S, Braun S, Jaeger C. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy. Curr Med Res Opin. 2011 Feb;27(2):355-63. doi: 10.1185/03007995.2010.542134. Epub 2010 Dec 20. PubMed PMID: 21166611.

6: de Kloe GE, Retra K, Geitmann M, Källblad P, Nahar T, van Elk R, Smit AB, van Muijlwijk-Koezen JE, Leurs R, Irth H, Danielson UH, de Esch IJ. Surface plasmon resonance biosensor based fragment screening using acetylcholine binding protein identifies ligand efficiency hot spots (LE hot spots) by deconstruction of nicotinic acetylcholine receptor α7 ligands. J Med Chem. 2010 Oct 14;53(19):7192-201. doi: 10.1021/jm100834y. PubMed PMID: 20828128.

7: Kobayashi M, Retra K, Figaroa F, Hollander JG, Ab E, Heetebrij RJ, Irth H, Siegal G. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification. J Biomol Screen. 2010 Sep;15(8):978-89. doi: 10.1177/1087057110375614. PubMed PMID: 20817886.

8: Geitmann M, Retra K, de Kloe GE, Homan E, Smit AB, de Esch IJ, Danielson UH. Interaction kinetic and structural dynamic analysis of ligand binding to acetylcholine-binding protein. Biochemistry. 2010 Sep 21;49(37):8143-54. doi: 10.1021/bi1006354. PubMed PMID: 20701394.

9: Retra K, Geitmann M, Kool J, Smit AB, de Esch IJ, Danielson UH, Irth H. Development of surface plasmon resonance biosensor assays for primary and secondary screening of acetylcholine binding protein ligands. Anal Biochem. 2010 Dec 1;407(1):58-64. doi: 10.1016/j.ab.2010.06.021. Epub 2010 Jun 17. PubMed PMID: 20599657.

10: Kool J, de Kloe GE, Bruyneel B, de Vlieger JS, Retra K, Wijtmans M, van Elk R, Smit AB, Leurs R, Lingeman H, de Esch IJ, Irth H. Online fluorescence enhancement assay for the acetylcholine binding protein with parallel mass spectrometric identification. J Med Chem. 2010 Jun 24;53(12):4720-30. doi: 10.1021/jm100230k. PubMed PMID: 20518527.

11: Alsafadi S, Tourpin S, André F, Vassal G, Ahomadegbe JC. P53 family: at the crossroads in cancer therapy. Curr Med Chem. 2009;16(32):4328-44. Review. PubMed PMID: 19754415.

12: van Riet E, Everts B, Retra K, Phylipsen M, van Hellemond JJ, Tielens AG, van der Kleij D, Hartgers FC, Yazdanbakhsh M. Combined TLR2 and TLR4 ligation in the context of bacterial or helminth extracts in human monocyte derived dendritic cells: molecular correlates for Th1/Th2 polarization. BMC Immunol. 2009 Feb 4;10:9. doi: 10.1186/1471-2172-10-9. PubMed PMID: 19193240; PubMed Central PMCID: PMC2672924.

13: Jonker N, Kool J, Krabbe JG, Retra K, Lingeman H, Irth H. Screening of protein-ligand interactions using dynamic protein-affinity chromatography solid-phase extraction-liquid chromatography-mass spectrometry. J Chromatogr A. 2008 Sep 26;1205(1-2):71-7. doi: 10.1016/j.chroma.2008.07.089. Epub 2008 Aug 7. PubMed PMID: 18715568.

14: van Riet E, Retra K, Adegnika AA, Jol-van der Zijde CM, Uh HW, Lell B, Issifou S, Kremsner PG, Yazdanbakhsh M, van Tol MJ, Hartgers FC. Cellular and humoral responses to tetanus vaccination in Gabonese children. Vaccine. 2008 Jul 4;26(29-30):3690-5. doi: 10.1016/j.vaccine.2008.04.067. Epub 2008 May 15. PubMed PMID: 18539369.

15: Retra K, Bleijerveld OB, van Gestel RA, Tielens AG, van Hellemond JJ, Brouwers JF. A simple and universal method for the separation and identification of phospholipid molecular species. Rapid Commun Mass Spectrom. 2008 Jun;22(12):1853-62. doi: 10.1002/rcm.3562. PubMed PMID: 18470873.

16: Kravchenko JE, Ilyinskaya GV, Komarov PG, Agapova LS, Kochetkov DV, Strom E, Frolova EI, Kovriga I, Gudkov AV, Feinstein E, Chumakov PM. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6302-7. doi: 10.1073/pnas.0802091105. Epub 2008 Apr 18. PubMed PMID: 18424558; PubMed Central PMCID: PMC2327210.

17: Retra K, van Riet E, Adegnika AA, Everts B, van Geest S, Kremsner PG, van Hellemond JJ, van der Kleij D, Tielens AG, Yazdanbakhsh M. Immunologic activity of schistosomal and bacterial TLR2 ligands in Gabonese children. Parasite Immunol. 2008 Jan;30(1):39-46. PubMed PMID: 18086015.

18: van Riet E, Adegnika AA, Retra K, Vieira R, Tielens AG, Lell B, Issifou S, Hartgers FC, Rimmelzwaan GF, Kremsner PG, Yazdanbakhsh M. Cellular and humoral responses to influenza in gabonese children living in rural and semi-urban areas. J Infect Dis. 2007 Dec 1;196(11):1671-8. Epub 2007 Oct 25. PubMed PMID: 18008252.

19: van Riet E, Wuhrer M, Wahyuni S, Retra K, Deelder AM, Tielens AG, van der Kleij D, Yazdanbakhsh M. Antibody responses to Ascaris-derived proteins and glycolipids: the role of phosphorylcholine. Parasite Immunol. 2006 Aug;28(8):363-71. PubMed PMID: 16879308.

20: Van Hellemond JJ, Retra K, Brouwers JF, van Balkom BW, Yazdanbakhsh M, Shoemaker CB, Tielens AG. Functions of the tegument of schistosomes: clues from the proteome and lipidome. Int J Parasitol. 2006 May 31;36(6):691-9. Epub 2006 Feb 28. Review. PubMed PMID: 16545817.